Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer. CANMAb will offer a high quality, more affordable option to breast cancer patients in India. Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25% cases are HER2-positive and eligible for treatment with CANMAb.
Lack of affordable treatment options has limited the extent of HER2 testing, and it is believed that the proportion of HER2-positive patients is probably higher.
Roche's Herceptin costs close to an eye-popping Rs 1 lakh for a month. CANMAb is being manufactured at Biocon's biologics facility in Bangalore and will be available to patients in February. The injection will be available in 150 mg to 440 mg variants priced in the range of Rs 19,500 to Rs 57,500 respectively. The 440 mg variety is 25% cheaper than the competition drug.
In addition, CANMAb's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.
This is the first drug developed by Biocon in partnership with Mylan, the US-based generic and specialty pharma company.
Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon Ltd, said: "The launch of CANMAb in India is an important milestone for our biosimilars program and demonstrates our ability to deliver on our promise of affordable innovation with a high quality, world- class product."
Anda sedang membaca artikel tentang
Biocon-Mylan develop biosimilar to treat cancer
Dengan url
http://cegahkeropostulang.blogspot.com/2014/01/biocon-mylan-develop-biosimilar-to.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Biocon-Mylan develop biosimilar to treat cancer
namun jangan lupa untuk meletakkan link
Biocon-Mylan develop biosimilar to treat cancer
sebagai sumbernya
0 komentar:
Posting Komentar